Table 1: Literature review of reported adult spinal AT/RT cases.
Reference |
Age/Sex |
Primary location |
Immunostain+ |
Leptomeningeal spread |
Primary treatment |
Survival (months) |
Bruch, et al., [8] |
21 F |
- |
EMA, Vim, CK |
- |
- |
6 |
Zarovnaya, et al., [9] |
43 M |
T11-L1 |
EMA |
Y |
UTR/Rad |
30 |
Kanoto, et al., [10] |
60 M |
C5-T1 |
- |
- |
- |
18 |
Gotti, et al., [11] |
19 F |
L4-L5 |
EMA, CAM, Vim, CD99 |
_ |
GTR/Rad/Chemo |
> 36 |
Sinha, et al., [12] |
65 M |
T11-L1 |
EMA, CAM, Vim, PanCK |
Y |
STR/Rad |
24 |
Li, et al., [13] |
23 F |
L2-L4 |
- |
- |
Rad/Chemo |
12 |
McGinity, et al., [14] |
43 F |
C1-C3 |
EMA, SMA, Vim |
N |
GTR/Rad |
> 6 |
Neromyliotis, et al., [15] |
19 F |
L4-S2 |
EMA, Vim, CK CD55 |
Y |
STR/Rad |
> 9 |
Sant, et al., [16] |
20 M |
C7-T2 |
EMA, CD99 |
- |
STR/Rad/Chemo |
- |
Present Study |
26 M |
L4 |
EMA, SMA |
Y |
GTR/Rad/Chemo |
12 |
Primary location: Location of primary lesion; Primary treatment: Treatment of primary lesion.
Treatment: GT: Gross total resection; STR: Sub-total resection; UTR: Resection unknown extent; Rad: Radiation. Immunostaining: CK: Cytokeratin; EMA: Epithelial membrane antigen; Vim: Vimentin; CAM: Cell adhesion molecule; PanC: Pancytokeratin; SMA: Smooth muscle antigen